Clinical trial NCT05712538: Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.
Official title: A Study in Two Parts: (Phase 1) A Randomized, Double-blinded, Placebo--controlled, Single-ascending-dose Study in Healthy Adult Subjects and (Phase 1b) an Open-label, Nested, Divided-dose Study in Adults With Cystic Fibrosis to Assess the Safety, Tolerability, and Pharmacokinetics of ARCT-032
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cystic Fibrosis
Keywords: Cystic Fibrosis, CF
Lead sponsor: Arcturus Therapeutics, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Novotech CRO
First posted: 2023-02-03
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double-blind, placebo controlled (Phase 1 only)
Primary purpose: TREATMENT

Brief summary: Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-032 in healthy adult subjects (Phase 1) and of two doses in Adults with Cystic Fibrosis (Phase 1b).

Detailed description: Phase 1 of this study is a single ascending dose, first-in-human study to determine the safety, tolerability, and pharmacokinetics (PK) of ARCT-032. After screening, healthy adult participants will be randomized 3:1 to inhale a single dose of nebulized ARCT-032 or placebo. There are 4 planned sequential dose cohorts. After dosing, participants will have follow-up assessments over a 4-week period.

Phase 1b in adults with cystic fibrosis will enroll after Phase 1 is completed and safety data are reviewed. Phase 1b is an open-label, two-dose study in adults with cystic fibrosis to assess the safety, tolerability, and pharmacokinetics of ARCT-032. After completion of screening, each participants will inhale two doses of nebulized ARCT-032 two days apart. Participants will have follow-up assessments over a 4-week period.

Eligibility criteria: Key Inclusion Criteria:

1. Phase 1: Healthy males or females aged 18 to 65 years at the time of informed consent.

   Phase 1b: Males or females aged 18 to 65 years with confirmed diagnosis of CF documented in subject's medical record
2. Body weight between 40-100Kg and body mass index between 16-35 kg/m2
3. Phase 1: Forced expiratory volume (FEV1) at screening \>85% of predicted value for age, sex, and height.

   Phase 1b: FEV1 at screening between 50% and 100% of predicted value
4. Surgically sterile or using an acceptable contraceptive method from the time of signing the informed consent form until at least 30 days after the last dose of study drug.
5. Phase 1b only: Subjects with CF on CFTR modulator therapy must be on a stable regimen for at least 2 months prior to screening.

Key Exclusion Criteria:

1. History of illness or condition that might pose an additional risk or may confound study results.
2. Pregnant or lactating (breast feeding)
3. History of severe allergic reaction to a liposomal product
4. Clinically significant abnormalities in Screening laboratory results
5. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B
6. Treatment with another investigational drug, biological agent, or device within 30 days of screening, or 5 half-lives of investigational drug, whichever is longer
7. Drug or alcohol abuse within the past year
8. History of moderate to heavy smoking or vaping (\>10 cigarettes/sessions per day) within 6 months prior to the dose of study drug. Participants must be willing to refrain from smoking or vaping within 1 week of dosing through Day 15
9. Systemic or inhaled corticosteroids within 3 months prior to screening (Phase 1 only).
10. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the Study

Primary outcomes:
measure: Incidence, severity and dose-relationship of AEs
timeFrame: 4 weeks
Secondary outcomes:
measure: Change in plasma area under the curve after single dose of ARCT-032
timeFrame: Up to 2 Weeks
measure: Maximum observed plasma concentration (Cmax) after single dose of ARCT-032
timeFrame: Up to 2 Weeks
measure: Time at which Cmax occurred after single dose of ARCT-032
timeFrame: Up to 2 Weeks
measure: AUC0-inf after single dose (Phase 1) or two doses (Phase 1b) of ARCT-032
timeFrame: Up to 2 Weeks
measure: T1/2 after single dose (Phase 1) or two doses (Phase 1b) of ARCT-032
timeFrame: Up to 2 Weeks
measure: CL after single dose (Phase 1) or two doses (Phase 1b) of ARCT-032
timeFrame: Up to 2 Weeks
measure: Vss after single dose (Phase 1) or two doses (Phase 1b) of ARCT-032
timeFrame: Up to 2 Weeks
Other outcomes:
Locations:
city: Christchurch
country: New Zealand
facility: New Zealand Clinical Research
Study officials:
affiliation: Arcturus Therapeutics
name: Clinical Program Director
role: STUDY_DIRECTOR
References: